Higher CPAP Adherence Tied to Reduction in Cardiovascular Events
FRIDAY, Oct. 6, 2023 (HealthDay News) -- Adherence to continuous positive airway pressure (CPAP) treatment is associated with a reduced risk for cardiovascular event recurrence, according to a review published in the Oct. 3 issue of the Journal of the American Medical Association.
Manuel Sánchez-de-la-Torre, Ph.D., from the University of Lleida in Spain, and colleagues conducted a systematic literature review and meta-analysis to assess the effect of CPAP treatment for obstructive sleep apnea (OSA) on the risk for adverse cardiovascular events. The analysis included data from 4,186 individual participants with established cardiovascular disease and OSA (50.1 percent receiving CPAP with mean adherence of 3.1 hours per day).
The researchers found that for the main outcome of first major adverse cardiac and cerebrovascular event (MACCE), the CPAP and non-CPAP groups had a similar occurrence (hazard ratio, 1.01; 95 percent confidence interval, 0.87 to 1.17). However, with good adherence to CPAP (four or more hours per day), treatment was associated with a reduced recurrence risk for MACCE (hazard ratio, 0.69; 95 percent confidence interval, 0.52 to 0.92).
"Adherence to CPAP was associated with a reduced MACCE recurrence risk, suggesting that treatment adherence is a key factor in secondary cardiovascular prevention in patients with OSA," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
3 Percent of Youth Testing Positive for COVID-19 in ED Have Severe Outcomes
FRIDAY, Jan. 14, 2022 (HealthDay News) -- Approximately 3 percent of severe acute...
Mindfulness Can Boost Your Mindset After Cardiac Arrest
WEDNESDAY, Nov 10, 2021 (HealthDay News) -- Shining a light on the powerful link...
¿Podrían los ácidos grasos omega 3 combatir al acné?
MIÉRCOLES, 18 de mayo de 2022 (HealthDay News) -- Hasta 50 millones de...
Una autopsia confirma la causa de una misteriosa enfermedad paralizante en los niños
JUEVES, 26 de mayo de 2022 (HealthDay News) -- Los investigadores quizá por fin...